Vox Markets has highlighted UK Companies well-placed to trade strongly through the Coronovirus pandemic with our "COVID-19 Crusaders" index.
The index aims to shine a spotlight on small-cap healthcare companies, advancing the development of novel vaccines, technology companies enabling this new remote-working world, and support service companies that through their distance learning platforms or eSports offerings make the lock-down just a little bit more bearable.
Avacta Group is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. It aims to address the lack of a durable response to current immunotherapies experienced by most patients and is believed to be developing a rapid test for COVID-19.
Byotrol is commercialising superior antimicrobial technologies. It recently announced it is working with Trystel, a manufacturer of infection control, contamination control and hygiene products, to develop a new surface disinfectant product for hospitals to help stop the spread of COVID-19.
Dev Clever is a software development company operating in the educational technology, digital gaming and mobile gaming markets. established in 2013. It has grown into a credible, recognised digital innovation brand with a range of blue-chip clients and educator customers. It has announced it plans to launch in the US, Canada and US from April 2020. The Group has announced it has seen an increase of 223% in demand from schools for its platforms since the outbreak of COVID-19.
UK based e-Therapeutics is a computer-based drug discovery platform holding a specialised approach to network biology. Its novel network-driven drug discovery ("NDD") methodology allows a new pathway of discovery to new and better drugs in a more efficient and effective way. The group has now offered up its rapid screening technology, “in silico”, in the quest to find an effective vaccine against COVID-19.
EVR Holdings is the owner and creator of MelodyVR – a market leader for entertainment in virtual reality, and the operator of the MelodyVR music platform. The Company recently reported a surge in sales for the platform, which allows fans to watch live music concerts through virtual reality, amid the lockdown caused by the COVID-19 outbreak .
Frontier IP Group is an AIM listed UK based specialist asset management group whose focus and purpose is to provide consultancy services to assist universities and research organisations in the commercialisation of intellectual property arising from their research. It recently announced that portfolio company Exscientia, a world leader in AI-driven drug discovery business, is to progress compounds that could rapidly become viable drugs for treating COVID-19.
Fusion Antibodies is a Belfast based, revenue generating and profitable CRO providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. Its mission is to enable pharma companies to develop innovative products in a timely and cost-effective manner. The group is involved with leading developers of therapeutic drugs and diagnostics working on solutions relating to Covid-19.
Genedrive is a rapid and low-cost molecular diagnostics platform for the identification and treatment selection of infectious diseases, human genotyping, animal health, pathogen identification, and other applications. The diagnostics firm is working on a clinically validated high throughput format for its COVID-19 test that could be available within the next two months.
GFINITY is a world leading eSports company created by gamers for the world's 2.2 billion gamers worldwide and directly to its competitive gaming consumers on its own platforms: Gfinity esports and RealSport101. Gfinity manages on and off-line competitions and industry‑leading content production. Relationships include EA SPORTS, Activision Blizzard, F1 Esports Series and the Forza Racing Championship. The Group has seen a significant spike of gamers on its platforms to more than 45 million in February due to the lockdown following the outbreak of COVID-19.
Inspiration Healthcare Group is a global supplier of medical technology for critical care, operating theatre and home healthcare applications. Its mission is to provide high quality innovative products to patients and caregivers around the world that help to improve patient outcomes and efficiencies of healthcare organisations with patient focused customer service and technical support. The group has received orders up to £4m from the NHS to supply medical equipment and ventilators in the fight against COVID-19.
Intelligent Ultrasound was founded 2004 and works with customers that are some of the world’s leading medical institutions. Its guiding principle is to develop world-class ultrasound software and simulation technologies that will improve the quality and speed of ultrasound scanning in the clinical environment. It recently announced the launch of a COVID-19 training module for its BodyWorks ultrasound simulator.
Modern Water owns, installs and operates world-leading membrane technologies and develops and supplies advanced systems for water monitoring. Its orders for water contamination detection bacteria consumables have increased by 46% year-on-year in the first quarter of 2020. The company believes the growing demand to be connected to the global Covid-19 public health crisis, from existing customers across Spain, Italy and China .
N4 Pharma is a specialist pharmaceutical company developing a novel silica nanoparticle delivery system – Nuvec®. Nuvec may be applicable for vaccines and therapeutics which has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines. The group is undertaking a proof of concept research project to demonstrate how Nuvec® could enhance a COVID-19 vaccine. N4 Pharma is a specialist pharmaceutical company developing a novel silica nanoparticle delivery system – Nuvec® – for vaccines and therapeutics which has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines. The group is undertaking a proof of concept research project to demonstrate how Nuvec® could enhance a COVID-19 vaccine.
Novacyt Group, an international specialist in cancer and infectious diseases, has diversified sales from diagnostic products used in LBC, oncology, microbiology, haematology and serology testing. The group has sold and received orders for over £17.8m of its CE-Mark and research use only COVID-19 tests. It is now teaming up with Yourgene Health to produce coronavirus testing products in the UK.
Open Orphan was founded in 2017, with the goal of becoming Europe’s leading rare disease and orphan drug focused pharma services company by a management team with extensive industry and financial expertise. The group has recommenced development of the world’s first commercial human coronavirus challenge study model which will see humans infected with the virus as part of the group’s efforts to develop a COVID-19 vaccine.
React Group was created over 20 years ago to provide a dedicated 24/7 specialist cleaning and decontamination service to the public sector. Today, it operates in a diverse range of market sectors from education and the leisure industry through to transport operators, police forces and the prison service. Since routine decontamination is insufficient and may spread, the group is working to decontaminate premises exposed to COVID-19.
Symphony Environmental Technologies is a global specialist in masterbatch and additive technologies that enhance the properties of plastic and complementary non-plastic products by making them biodegradable, or lethal to bacteria, fungi, algae, moulds, insects, fouling and fire. The Company recently announced it is testing its antimicrobial anti-microbial d2p technology to determine whether it can also be effective against viruses such as Covid-19.
Synairgen is focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and develop novel therapies for respiratory disease. The company is currently leading a clinical trial across UK hospitals with a prevention drug it hopes will stop sufferers of the COVID-19 from falling seriously ill .
Tekcapital is the world’s largest university network for open innovation with an objective to create value from investing in new, university-developed intellectual properties. The Group’s portfolio firm, Belluscura, has filed a patent for a portable oxygen enrichment system to treat patients suffering from respiratory illnesses brought on by infections such as COVID-19.
Totally is one of the UK’s largest out-of-hospital care providers delivering high-quality planned, urgent and insourcing healthcare across the UK and Ireland. The Group recently said it is providing a number of additional services to support the NHS as it deals with the Covid-19 outbreak.
Tristel is a manufacturer of infection control, contamination control and hygiene products with four principal activities; Medical Instrument Disinfection under the Tristel brand Hospital Surface Disinfection under the Cache brand Cleanroom, pharma and lab under the Crystel brand Infection prevention in animal healthcare under the Anistel brand. The group is working with Byotrol – a micro-cap provider of antimicrobial technologies – to develop a new surface disinfectant product for hospitals to help stop the spread of COVID-19.
Educational group, Wey Education uses digital technology to operate its two established divisions – InterHigh, a non-selective fee paying online secondary school, established in 2005 and Academy21, B2B division serving other educational providers, schools, local authorities and other public bodies. The group is witnessing further demand with the widespread shift to online education in the wake of the COVID-19 and government lockdowns.
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services, working in partnership with global leaders in DNA technology to advance diagnostic science. The group’s manufacturing facility in Manchester will be used to expand Novacyt’s production capacity of a COVID-19 test.